← Oncology Approval Tracker

FDA DECISION ·

Abecma

idecabtagene vicleucel · Celgene (Bristol Myers Squibb)

FDA approvalNew or expanded indicationMultiple myeloma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with relapsed or refractory multiple myeloma after at least two prior lines that included an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 monoclonal antibody.

LAMPGEN ANALYSIS

Why it matters

The label moved BCMA-directed CAR T treatment earlier for patients already exposed to three major drug classes.

What research teams should watch

Verify the complete line history and document leukapheresis, bridging therapy and infusion readiness as separate milestones.

PRIMARY RECORDS

Sources